Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. on December 14, 2016, reporting an event that occurred on December 8, 2016. The filing details the entry into a definitive agreement with Wyeth LLC, a wholly-owned subsidiary of Pfizer Inc.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on the terms of a new licensing agreement.
- Contingent Payments: Up to $17.5 million in aggregate cash payments to Wyeth upon achievement of clinical, regulatory, and commercial milestones.
- Royalties: Single-digit royalty on net Product sales on a country-by-country basis following commercialization.
Material Changes
The Company entered into a new definitive agreement with Wyeth to replace a research and license agreement that was terminated on June 1, 2015. Under the new terms:
- Wyeth granted Catalyst an exclusive license to proprietary rights for Factor VIIa variants (CB 813a and CB 813d).
- Wyeth transferred documentation related to development, manufacturing, and testing, including the Investigational New Drug application.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the agreement. The future financial impact is contingent upon the successful development and commercialization of the Products. No specific risks or contingencies beyond the standard milestone and royalty obligations were detailed in this specific filing text.
Investor Verification Checklist
- Verify the specific clinical, regulatory, and commercial milestones required to trigger the $17.5 million in payments.
- Confirm the exact percentage of the "single-digit royalty" and the duration of the royalty term.
- Review the status of the Investigational New Drug application transferred from Wyeth.
- Assess the Company's current cash position to determine its ability to fund future development without immediate revenue.